Leerink Partnrs Estimates NeuroPace FY2029 Earnings

NeuroPace, Inc. (NASDAQ:NPCE) – Analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for NeuroPace in a research note issued to investors on Tuesday, January 28th. Leerink Partnrs analyst M. Kratky anticipates that the company will post earnings of $0.43 per share for the year. The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share.

NeuroPace (NASDAQ:NPCE) last issued its earnings results on Tuesday, November 12th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.07. The company had revenue of $21.06 million for the quarter, compared to the consensus estimate of $19.33 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. During the same period in the previous year, the firm earned ($0.28) earnings per share.

NPCE has been the topic of several other reports. JPMorgan Chase & Co. raised their target price on NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. UBS Group assumed coverage on NeuroPace in a research report on Tuesday, January 21st. They issued a “buy” rating and a $17.00 price objective on the stock. Finally, Wells Fargo & Company upped their target price on NeuroPace from $13.00 to $17.00 and gave the company an “overweight” rating in a report on Thursday. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $14.80.

NeuroPace Price Performance

NPCE stock opened at $14.19 on Thursday. The stock has a market capitalization of $423.57 million, a price-to-earnings ratio of -14.19 and a beta of 2.02. The firm’s 50-day moving average price is $11.75 and its two-hundred day moving average price is $8.81. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03. NeuroPace has a 12-month low of $5.45 and a 12-month high of $18.15.

Insider Buying and Selling at NeuroPace

In other NeuroPace news, insider Martha Morrell sold 3,200 shares of the firm’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $15.01, for a total transaction of $48,032.00. Following the completion of the transaction, the insider now owns 87,062 shares of the company’s stock, valued at approximately $1,306,800.62. This trade represents a 3.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 22.20% of the company’s stock.

Institutional Trading of NeuroPace

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Millennium Management LLC increased its position in NeuroPace by 13.3% during the 2nd quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock valued at $5,186,000 after buying an additional 80,324 shares in the last quarter. KCK LTD. purchased a new stake in shares of NeuroPace in the fourth quarter worth $58,981,000. Barclays PLC increased its holdings in shares of NeuroPace by 346.0% during the third quarter. Barclays PLC now owns 20,633 shares of the company’s stock valued at $144,000 after acquiring an additional 16,007 shares in the last quarter. State Street Corp raised its position in shares of NeuroPace by 9.1% in the 3rd quarter. State Street Corp now owns 155,490 shares of the company’s stock worth $1,084,000 after purchasing an additional 12,912 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in NeuroPace by 8.7% in the 3rd quarter. Geode Capital Management LLC now owns 317,192 shares of the company’s stock worth $2,211,000 after purchasing an additional 25,330 shares in the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.